436 reports of this reaction
1.6% of all DARUNAVIR reports
#15 most reported adverse reaction
OSTEOPOROSIS is the #15 most commonly reported adverse reaction for DARUNAVIR, manufactured by Janssen Products LP. There are 436 FDA adverse event reports linking DARUNAVIR to OSTEOPOROSIS. This represents approximately 1.6% of all 26,718 adverse event reports for this drug.
Patients taking DARUNAVIR who experience osteoporosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OSTEOPOROSIS is a less commonly reported adverse event for DARUNAVIR, but still significant enough to appear in the safety profile.
In addition to osteoporosis, the following adverse reactions have been reported for DARUNAVIR:
The following drugs have also been linked to osteoporosis in FDA adverse event reports:
OSTEOPOROSIS has been reported as an adverse event in 436 FDA reports for DARUNAVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
OSTEOPOROSIS accounts for approximately 1.6% of all adverse event reports for DARUNAVIR, making it a notable side effect.
If you experience osteoporosis while taking DARUNAVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.